Edward M. Chan

2.8k total citations · 1 hit paper
43 papers, 1.4k citations indexed

About

Edward M. Chan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hematology. According to data from OpenAlex, Edward M. Chan has authored 43 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 15 papers in Hematology. Recurrent topics in Edward M. Chan's work include Advanced Breast Cancer Therapies (17 papers), CAR-T cell therapy research (8 papers) and Multiple Myeloma Research and Treatments (8 papers). Edward M. Chan is often cited by papers focused on Advanced Breast Cancer Therapies (17 papers), CAR-T cell therapy research (8 papers) and Multiple Myeloma Research and Treatments (8 papers). Edward M. Chan collaborates with scholars based in United States, Canada and United Kingdom. Edward M. Chan's co-authors include Damien M. Cronier, Lawrence M. Gelbert, Rose T. Ajamie, Shufen Cai, Alfonso de Dios, Graham N. Wishart, Miriam Del Prado, Marı́a José Lallena, Raquel Torres and Concepción Sánchez‐Martínez and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Edward M. Chan

42 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

2014 446 citations Lawrence M. Gelbert, Shufen Cai et al. Investigational New Drugs profile →

Peers

Edward M. Chan

ONCOL

PRM

GENET

HEMAT

Linnea Chap United States

Paul K. Stockman United Kingdom

David Demanse Switzerland

Paul Conkling United States

E.L. Kwak United States

Katherine E. Hutchinson United States

Giorgia Migliardi Italy

Marlies H.G. Langenberg Netherlands

Katharine Hazell Switzerland

Mikhail Shtivelband United States

Linnea Chap United States

Edward M. Chan

1.0k ×1.0

ONCOL

367 ×0.4

PRM

662 ×1.6

115 ×0.4

GENET

207 ×1.1

HEMAT

Citations per year, relative to Edward M. Chan Edward M. Chan (= 1×) peers Linnea Chap

Countries citing papers authored by Edward M. Chan

Since Specialization

Citations

This map shows the geographic impact of Edward M. Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward M. Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward M. Chan more than expected).

Fields of papers citing papers by Edward M. Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward M. Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward M. Chan. The network helps show where Edward M. Chan may publish in the future.

Co-authorship network of co-authors of Edward M. Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Edward M. Chan. A scholar is included among the top collaborators of Edward M. Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward M. Chan. Edward M. Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bahlis, Nizar J., Caitlin Costello, Noopur Raje, et al.. (2023). Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nature Medicine. 29(10). 2570–2576. 76 indexed citations

Witzig, Thomas E., Kami J. Maddocks, Sven de Vos, et al.. (2019). Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 37(15_suppl). 7519–7519. 12 indexed citations

Tate, Sonya C., et al.. (2017). A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients. Clinical Pharmacokinetics. 57(3). 335–344. 55 indexed citations

Chan, Edward M., et al.. (2017). Therapeutic temperature management (TTM): post-resuscitation care for adult cardiac arrest, with recommendations from the National TTM Workgroup. Singapore Medical Journal. 58(7). 408–410. 11 indexed citations

Goldman, Jonathan W., Lee S. Rosen, Anthony W. Tolcher, et al.. (2017). Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer. Investigational New Drugs. 36(4). 629–637. 13 indexed citations

Fujiwara, Yutaka, Kenji Tamura, Shunsuke Kondo, et al.. (2016). Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 78(2). 281–288. 50 indexed citations

Pant, Shubham, Suzanne F. Jones, Carla Kurkjian, et al.. (2016). A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. European Journal of Cancer. 56. 1–9. 72 indexed citations

Kondo, Shunsuke, Nobuyuki Yamamoto, Keita Tamura, et al.. (2015). 314 Phase 1 study of abemaciclib, a CDK 4 and 6 inhibitor, as a single agent for Japanese patients with advanced cancer. European Journal of Cancer. 51. S59–S59. 3 indexed citations

Tate, Sonya C., Shufen Cai, Rose T. Ajamie, et al.. (2014). Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts. Clinical Cancer Research. 20(14). 3763–3774. 100 indexed citations

10.

Yadav, Vipin, Teresa F. Burke, Lysiane Huber, et al.. (2014). The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation. Molecular Cancer Therapeutics. 13(10). 2253–2263. 104 indexed citations

11.

Gelbert, Lawrence M., Shufen Cai, Xi Lin, et al.. (2014). Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Investigational New Drugs. 32(5). 825–837. 446 indexed citations breakdown →

12.

Goldman, Jonathan W., Leena Gandhi, Amita Patnaik, et al.. (2014). Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer.. Journal of Clinical Oncology. 32(15_suppl). 8026–8026. 26 indexed citations

13.

Sayar, Hamid, Rebecca J. Chan, Christie M. Orschell, et al.. (2011). Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: A study of the Hoosier Oncology Group. Leukemia Research. 35(8). 1108–1110. 5 indexed citations

14.

Gelbert, Lawrence M., Shufen Cai, Xi Lin, et al.. (2011). Abstract B233: Identification and characterization of LY2835219: A potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) with broad in vivo antitumor activity.. Molecular Cancer Therapeutics. 10(11_Supplement). B233–B233. 14 indexed citations

15.

Sargent, Daniel J., T. C. Smyrk, Anthony F. Shields, et al.. (2010). ステージIII結腸癌を切除したKRAS野生型(WT)患者(pts)におけるセツキシマブ(Cmab)の有無にかかわらずmFOLFOX6アジュバント治療:NCCTG群間第3相試験NO147の結果. Journal of Clinical Oncology. 28. 959. 1 indexed citations

16.

Yang, Zhenyun, Takako Kondo, Sarah C. Nabinger, et al.. (2009). Increased c-Jun Expression and Reduced GATA2 Expression Promote Aberrant Monocytic Differentiation Induced by Activating PTPN11 Mutants. Molecular and Cellular Biology. 29(16). 4376–4393. 20 indexed citations

17.

Chan, Edward M., Rebecca J. Chan, Robert J. Goulet, et al.. (2007). MOZ and MOZ-CBP cooperate with NF-κB to activate transcription from NF-κB–dependent promoters. Experimental Hematology. 35(12). 1782–1792. 22 indexed citations

18.

Chan, Edward M.. (2005). AML1-FOG2 fusion protein in myelodysplasia. Blood. 105(11). 4523–4526. 26 indexed citations

19.

Chan, Edward M., et al.. (2001). Effect of Ubidecarenone on Warfarin Anticoagulation and Pharmacokinetics of Warfarin Enantiomers in Rats. Drug metabolism and drug interactions. 18(2). 99–122. 11 indexed citations

20.

Chan, Edward M., et al.. (2000). Tissue-Specific Regulatory Elements in the Human Alcohol Dehydrogenase 6 Gene. DNA and Cell Biology. 19(8). 487–497. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact